MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition for Inflammatory Disease Research

Executive Summary: MCC950 sodium (B7946, APExBIO) is a highly selective, small-molecule inhibitor of the NLRP3 inflammasome (IC50 7.5 nM in BMDMs) that blocks both canonical and noncanonical activation pathways, but not other inflammasomes such as AIM2 or NLRC4 [Product page]. MCC950 sodium dose-dependently inhibits IL-1β release in human and murine macrophages and PBMCs while sparing TNF-α secretion, confirming its specificity [Yuan et al., 2022]. In vivo, it reduces serum IL-1β and IL-6 in LPS-challenged mice and attenuates disease in experimental autoimmune encephalomyelitis. MCC950 sodium is soluble at ≥124 mg/mL in water and is stable at -20°C. It is widely validated and recommended for dissecting the NLRP3 inflammasome signaling pathway in inflammation and autoimmune models [Strategic NLRP3 Inhibition].

Biological Rationale

The NLRP3 inflammasome is a multi-protein complex critical for innate immune responses. It is activated by cellular stress, infection, or metabolic signals, leading to caspase-1 activation and the release of pro-inflammatory cytokines such as IL-1β and IL-18 (Yuan et al., 2022). Dysregulated NLRP3 activation contributes to the pathogenesis of diseases including atherosclerosis, multiple sclerosis, steatohepatitis, and steroid-insensitive asthma. Targeting NLRP3 is central to modulating inflammasome-mediated inflammation and pyroptosis in both macrophage and endothelial cell models [Advanced Mechanisms]. MCC950 sodium, also known as CRID3 sodium salt, is designed to selectively inhibit NLRP3 activation without interfering with related inflammasomes such as AIM2, NLRC4, or NLRP1.

Mechanism of Action of MCC950 sodium

MCC950 sodium directly binds to the NLRP3 protein, blocking its ATPase activity, thereby preventing conformational changes required for inflammasome assembly. This inhibition halts downstream caspase-1 activation and subsequent maturation of IL-1β and IL-18 (Yuan et al., 2022). MCC950 sodium is effective at nanomolar concentrations (IC50 7.5 nM in murine BMDMs) and demonstrates comparable potency in human monocyte-derived macrophages (HMDMs). It efficiently inhibits both canonical (e.g., LPS/ATP-induced) and noncanonical (e.g., cytosolic LPS) activation of NLRP3, distinguishing it from less selective inflammasome inhibitors. The compound does not affect TNF-α secretion, demonstrating its specificity for the NLRP3-IL-1β axis.

Evidence & Benchmarks

• MCC950 sodium inhibits NLRP3 activation in murine BMDMs with an IC50 of 7.5 nM, determined by IL-1β ELISA following LPS/ATP stimulation (Yuan et al., 2022).
• MCC950 sodium blocks both canonical and noncanonical NLRP3 activation pathways without affecting AIM2, NLRC4, or NLRP1 inflammasomes (Yuan et al., 2022).
• In HUVECs, MCC950 sodium inhibits H₂O₂-induced pyroptosis, reducing caspase-1 activation and IL-1β release (Yuan et al., 2022).
• Intraperitoneal injection of MCC950 sodium in C57BL/6 mice reduces serum IL-1β and IL-6 after LPS challenge and attenuates disease severity in experimental autoimmune encephalomyelitis (Yuan et al., 2022).
• MCC950 sodium does not impair TNF-α secretion in human PBMCs, confirming its selectivity for the NLRP3/IL-1β pathway (Yuan et al., 2022).

This article extends the in-depth mechanistic review "MCC950 Sodium in Vascular Inflammation: Advanced Mechanisms" by providing new benchmarks for endothelial cell pyroptosis and NLRP3 selectivity.

Applications, Limits & Misconceptions

MCC950 sodium is validated for use in:

• In vitro assays with bone marrow-derived macrophages (BMDMs), human monocyte-derived macrophages (HMDMs), and human PBMCs for NLRP3-dependent IL-1β secretion.
• Endothelial cell models of oxidative stress and pyroptosis (e.g., HUVECs exposed to H₂O₂).
• In vivo models including LPS-induced systemic inflammation and experimental autoimmune encephalomyelitis (multiple sclerosis model) in C57BL/6 mice.
• Dissecting canonical and noncanonical inflammasome signaling in inflammatory and autoimmune disease research.

For a broader translational perspective, see "MCC950 Sodium (CRID3): Strategic Precision for Translational Models", which this article updates with new evidence on endothelial pyroptosis models.

Common Pitfalls or Misconceptions

• Non-selective inhibition: MCC950 sodium does not inhibit AIM2, NLRC4, or NLRP1 inflammasomes and is therefore not a pan-inflammasome inhibitor (Yuan et al., 2022).
• Stability: Long-term storage of MCC950 sodium solutions at room temperature or above -20°C can reduce potency. Only store stock solutions at -20°C and avoid repeated freeze-thaw cycles (APExBIO).
• Species specificity: While effective in human and murine macrophages, efficacy in other species should be empirically validated.
• Non-effect on TNF-α: MCC950 sodium does not block TNF-α secretion; it is not a general cytokine inhibitor (Yuan et al., 2022).
• Not a therapeutic drug: MCC950 sodium is for research use only and not approved for clinical therapeutic use.

Workflow Integration & Parameters

MCC950 sodium is supplied as a sodium salt (CAS 256373-96-3) and should be stored dry at -20°C. It is soluble at ≥124 mg/mL in water, ≥21.45 mg/mL in DMSO, and ≥43 mg/mL in ethanol. For in vitro assays, typical working concentrations range from 10 nM to 10 μM, depending on cell type and endpoint. For in vivo studies, intraperitoneal dosing in C57BL/6 mice is common, with dose, frequency, and duration tailored to the disease model. Always prepare fresh solutions or store aliquots at -20°C to maintain stability. For detailed protocol guidance, refer to the MCC950 sodium product page (APExBIO).

This article clarifies and updates the guidance in "MCC950 Sodium: Precision NLRP3 Inflammasome Inhibition for Research" by including new benchmarking data for endothelial models and practical workflow tips.

Conclusion & Outlook

MCC950 sodium is the leading selective NLRP3 inflammasome inhibitor for mechanistic studies in inflammation, pyroptosis, and autoimmune disease models. Its nanomolar potency, high specificity, and broad validation in human and murine assays make it a cornerstone tool for dissecting NLRP3-driven pathways. As research advances in inflammasome biology and translational models, MCC950 sodium (APExBIO B7946) will remain foundational for precise modulation of the NLRP3 inflammasome and IL-1β signaling. For comprehensive product details or ordering, visit the MCC950 sodium product page.